Featured Pharma Online Editorial
-
AI In Action: Evaluating Project Assessment
11/9/2026
In this four-part series of interviews at ISPE’s Annual Meeting & Expo, I talk to experts who have made advances in AI, all in different areas, to do their job more efficiently. We explore project assessment here, but will also explore cleaning validation, continuous verification and risk assessment in future segments.
-
IT/OT Convergence Could Lighten Biopharma's Automation Burden
11/9/2026
Integration lets frameworks talk to each other through middleware. Convergence brings them under the same architecture, which can can reduce costs and maintenance.
-
Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
11/6/2026
Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
11/4/2026
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
-
The EU Overhauls Pharma Laws: What You Need To Know
11/2/2026
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
10/28/2026
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
-
Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
10/22/2026
Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.
-
Is Your Supply Chain Ready For The End Of Class VI?
10/21/2026
Revisions to USP <87> and <88> update biological reactivity testing — changes that are especially important for companies that rely on single-use technology.
-
The Orange Book's Blind Spot: Process Stability And Capability
10/5/2026
The current system for assuring therapeutic equivalence contains structural blind spots. Companies must evolve rather than merely adding corrective actions.
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
10/2/2026
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.